Pluripotent stem cells in research and treatment of hemoglobinopathies

Cold Spring Harbor Perspectives in Medicine

Volumn 2, Issue 4, 2012, Pages

  Arora, Natasha ^a,b,c   Daley, George Q ^a,b,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD STEM CELL INSTITUTE   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN BETA CHAIN; HEMOGLOBIN GAMMA CHAIN; HLA A ANTIGEN; HLA B ANTIGEN; HLA DR ANTIGEN;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CELL BANK; CELL DIFFERENTIATION; DISEASE MODEL; GENE THERAPY; HEALTH CARE FACILITY; HEMATOPOIETIC STEM CELL; HEMOGLOBINOPATHY; HUMAN; NONHUMAN; PLURIPOTENT STEM CELL; SICKLE CELL ANEMIA; STEM CELL TRANSPLANTATION; THALASSEMIA; ANIMAL; CYTOLOGY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; REVIEW; TRANSPLANTATION;

ANIMALS; CELL DIFFERENTIATION; DISEASE MODELS, ANIMAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOGLOBINOPATHIES; HUMANS; INDUCED PLURIPOTENT STEM CELLS; PLURIPOTENT STEM CELLS;

EID: 84883154824     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a011841     Document Type: Article

References (87)

1. Aasen T, Raya A, Barrero MJ, Garreta E, Consiglio A, Gonzalez F, Vassena R, Bilic J, Pekarik V, Tiscornia G, et al. 2008. Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. Nat Biotechnol 26: 1276-1284.
2. Alebouyeh M, Moussavi F, Haddad-Deylami H, Vossough P. 2004. Hydroxyurea in the treatment of major β-thalassemia and importance of genetic screening. Ann Hematol 83: 430-433.
3. Ben-Yosef D, Malcov M, Eiges R. 2008. PGD-derived human embryonic stem cell lines as a powerful tool for the study of human genetic disorders. Mol Cell Endocrinol 282: 153-158.
4. Brittenham GM, Schechter AN, Noguchi CT. 1985. Hemoglobin S polymerization: Primary determinant of the hemolytic and clinical severity of the sickling syndromes. Blood 65: 183-189.
5. Chang J, Lu RH, Xu SM, Meneses J, Chan K, Pedersen R, Kan YW. 1996. Inactivation of mouse α-globin gene by homologous recombination: Mouse model of hemoglobin H disease. Blood 88: 1846-1851.
6. Chang KH, Nelson AM, Cao H, Wang L, Nakamoto B, Ware CB, Papayannopoulou T. 2006. Definitive-like erythroid cells derived from human embryonic stem cells coexpress high levels of embryonic and fetal globins with little or no adult globin. Blood 108: 1515-1523.
7. Chang KH, Bonig H, Papayannopoulou T. 2011. Generation and characterization of erythroid cells from human embryonic stem cells and induced pluripotent stem cells: An overview. Stem Cells Int 2011: 791604.
8. + progenitors with distinct characteristics. PLoS ONE 6: e14733.
9. Choi KD, Yu J, Smuga-Otto K, Salvagiotto G, Rehrauer W, Vodyanik M, Thomson J, Slukvin I. 2009. Hematopoietic and endothelial differentiation of human induced pluripotent stem cells. Stem Cells 27: 559-567.
10. Coles SM, Klein HG, Holland PV. 1981. Alloimmunization in two multitransfused patient populations. Transfusion 21: 462-466.
11. Cox JV, Steane E, Cunningham G, Frenkel EP. 1988. Risk of alloimmunization and delayed hemolytic transfusion reactions in patients with sickle cell disease. Arch Intern Med 148: 2485-2489.
12. Crepeau RH, Dykes G, Garrell R, Edelstein SJ. 1978. Diameter of haemoglobin S fibres in sickled cells. Nature 274: 616-617.
13. Davies SC, McWilliam AC, Hewitt PE, Devenish A, Brozovic M. 1986. Red cell alloimmunization in sickle cell disease. Br J Haematol 63: 241-245.
14. Dykes GW, Crepeau RH, Edelstein SJ. 1979. Three-dimensional reconstruction of the 14-filament fibers of hemoglobin S. J Mol Biol 130: 451-472.
15. Eaton WA, Hofrichter J. 1987. Hemoglobin S gelation and sickle cell disease. Blood 70: 1245-1266.
16. Evans MJ, Kaufman MH. 1981. Establishment in culture of pluripotential cells from mouse embryos. Nature 292: 154-156.
17. Fan Y, Jiang Y, Chen X, Ou Z, Yin Y, Huang S, Kou Z, Li Q, Long X, Liu J, et al. 2011. Derivation of cloned human blastocysts by histone deacetylase inhibitor treatment after somatic cell nuclear transfer with β-thalassemia fibroblasts. Stem Cells Dev 20: 1951-1959.
18. Feng Q, Lu SJ, Klimanskaya I, Gomes I, Kim D, Chung Y, Honig GR, Kim KS, Lanza R. 2010. Hemangioblastic derivatives from human induced pluripotent stem cells exhibit limited expansion and early senescence. Stem Cells 28: 704-712.
19. Fessas P. 1963. Inclusions of hemoglobin erythroblasts and erythrocytes of thalassemia. Blood 21: 21-32.
20. Fessas P, Loukopoulos D, Thorell B. 1965. Absorption spectra of inclusion bodies in β-thalassemia. Blood 25: 105-109.
21. Han XD, Lin C, Chang J, Sadelain M, Kan YW. 2007. Fetal gene therapy of α-thalassemia in a mouse model. Proc Natl Acad Sci 104: 9007-9011.
22. Hanna J, Wernig M, Markoulaki S, Sun CW, Meissner A, Cassady JP, Beard C, Brambrink T, Wu LC, Townes TM, et al. 2007. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 318: 1920-1923.
23. Hargus G, Cooper O, Deleidi M, Levy A, Lee K, Marlow E, Yow A, Soldner F, Hockemeyer D, Hallett PJ, et al. 2010. Differentiated Parkinson patient-derived induced pluripotent stem cells grow in the adult rodent brain and reduce motor asymmetry in Parkinsonian rats. Proc Natl Acad Sci 107: 15921-15926.
24. Hockemeyer D, Soldner F, Beard C, Gao Q, Mitalipova M, DeKelver RC, KatibahGE, Amora R, Boydston EA, Zeitler B, et al. 2009. Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. Nat Biotechnol 27: 851-857.
25. Hockemeyer D, Wang H, Kiani S, Lai CS, Gao Q, Cassady JP, Cost GJ, Zhang L, Santiago Y, Miller JC, et al. 2011. Genetic engineering of human pluripotent cells using TALE nucleases. Nat Biotechnol 29: 731-734.
26. Hofrichter J, Ross PD, Eaton WA. 1974. Kinetics and mechanism of deoxyhemoglobin S gelation: A new approach to understanding sickle cell disease. Proc Natl Acad Sci 71: 4864-4868.
27. Imren S, Payen E, Westerman KA, Pawliuk R, Fabry ME, Eaves CJ, Cavilla B, Wadsworth LD, Beuzard Y, Bouhassira EE, et al. 2002. Permanent and panerythroid correction of murine β thalassemia by multiple lentiviral integration in hematopoietic stem cells. Proc Natl Acad Sci 99: 14380-14385.
28. Ingram VM. 1956. A specific chemical difference between the globins of normal human and sickle-cell anaemia haemoglobin. Nature 178: 792-794.
29. Ingram VM. 1957. Gene mutations in human haemoglobin: The chemical difference between normal and sickle cell haemoglobin. Nature 180: 326-328.
30. Ingram VM, Stretton AO. 1959. Genetic basis of the thalassaemia diseases. Nature 184: 1903-1909.
31. International Stem Cell Initiative, Adewumi O, Aflatoonian B, Ahrlund-RichterL, Amit M, Andrews PW, Beighton G, Bello PA, Benvenisty N, Berry LS, et al. 2007. Characterization of human embryonic stem cell lines by the International Stem Cell Initiative. Nat Biotechnol 25: 803-816.
32. Kaufman DS. 2009. Toward clinical therapies using hematopoietic cells derived from human pluripotent stem cells. Blood 114: 3513-3523.
33. Kim K, Zhao R, Doi A, Ng K, Unternaehrer J, Cahan P, Hongguang H, Loh YH, Aryee MJ, Lensch MW, et al. 2011. Donor cell type can influence the epigenome and differentiation potential of human induced pluripotent stem cells. Nat Biotechnol 29: 1117-1119.
34. Koren A, Levin C, Dgany O, Kransnov T, Elhasid R, Zalman L, Palmor H, TamaryH. 2008. Response to hydroxyurea therapy in beta-thalassemia. Am J Hematol 83(5): 366-370.
35. Ledran MH, Krassowska A, Armstrong L, Dimmick I, Renstrom J, Lang R, YungS, Santibanez-Coref M, Dzierzak E, Stojkovic M, et al. 2008. Efficient hematopoietic differentiation of human embryonic stem cells on stromal cells derived from hematopoietic niches. Cell Stem Cell 3: 85-98.
36. Letvin NL, Linch DC, Beardsley GP, McIntyre KW, Nathan DG. 1984. Augmentation of fetal-hemoglobin production in anemic monkeys by hydroxyurea. N Engl J Med 310: 869-873.
37. Lisowski L, Sadelain M. 2007. Locus control region elements HS1 and HS4 enhance the therapeutic efficacy of globin gene transfer in β-thalassemic mice. Blood 110: 4175-4178.
38. Loh YH, Agarwal S, Park IH, Urbach A, Huo H, Heffner GC, Kim K, Miller JD, NgK, Daley GQ. 2009. Generation of induced pluripotent stem cells from human blood. Blood 113: 5476-5479.
39. Lu SJ, Feng Q, Park JS, Vida L, Lee BS, Strausbauch M, Wettstein PJ, Honig GR, Lanza R. 2008. Biologic properties and enucleation of red blood cells from human embryonic stem cells. Blood 112: 4475-4484.
40. Ma F, Ebihara Y, Umeda K, Sakai H, Hanada S, Zhang H, Zaike Y, Tsuchida E, Nakahata T, Nakauchi H, et al. 2008. Generation of functional erythrocytes from human embryonic stem cell-derived definitive hematopoiesis. Proc Natl Acad Sci 105: 13087-13092.
41. Maehr R, Chen S, Snitow M, Ludwig T, Yagasaki L, Goland R, Leibel RL, MeltonDA. 2009. Generation of pluripotent stem cells from patients with type 1 diabetes. Proc Natl Acad Sci 106: 15768-15773.
42. Mali P, Ye Z, Hommond HH, Yu X, Lin J, Chen G, Zou J, Cheng L. 2008. Improved efficiency and pace of generating induced pluripotent stem cells from human adult and fetal fibroblasts. Stem Cells 26: 1998-2005.
43. Martin GR. 1981. Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. Proc Natl Acad Sci 78(12): 7634-7638.
44. Mateizel I, De Temmerman N, Ullmann U, Cauffman G, Sermon K, Van de VeldeH, De Rycke M, Degreef E, Devroey P, Liebaers I, et al. 2006. Derivation of human embryonic stem cell lines from embryos obtained after IVF and after PGD for monogenic disorders. Hum Reprod 21: 503-511.
45. May C, Rivella S, Callegari J, Heller G, Gaensler KM, Luzzatto L, Sadelain M. 2000. Therapeutic haemoglobin synthesis in β-thalassaemic mice expressing lentivirus-encoded human β-globin. Nature 406: 82-86.
46. May C, Rivella S, Chadburn A, Sadelain M. 2002. Successful treatment of murine β-thalassemia intermedia by transfer of the human β-globin gene. Blood 99: 1902-1908.
47. Nakajima F, Tokunaga K, Nakatsuji N. 2007. Human leukocyte antigen matching estimations in a hypothetical bank of human embryonic stem cell lines in the Japanese population for use in cell transplantation therapy. Stem Cells 25: 983-985.
48. Nakatsuji N, Nakajima F, Tokunaga K. 2008. HLA-haplotype banking and iPS cells. Nat Biotechnol 26: 739-740.
49. Nishino T, Cao H, Stamatoyannopoulos G, Emery DW. 2006. Effects of human γ-globin in murine β-thalassaemia. Br J Haematol 134: 100-108.
50. Noguchi CT, Schechter AN. 1981. The intracellular polymerization of sickle hemoglobin and its relevance to sickle cell disease. Blood 58: 1057-1068.
51. Okita K, Yamanaka S. 2011. Induced pluripotent stem cells: Opportunities and challenges. Philos Trans R Soc Lond B Biol Sci 366: 2198-2207.
52. Olivier EN, Qiu C, Velho M, Hirsch RE, Bouhassira EE. 2006. Large-scale production of embryonic red blood cells from human embryonic stem cells. Exp Hematol 34: 1635-1642.
53. Orlina AR, Unger PJ, Koshy M. 1978. Post-transfusion alloimmunization in patients with sickle cell disease. Am J Hematol 5: 101-106.
54. Osafune K, Caron L, Borowiak M, Martinez RJ, Fitz-Gerald CS, Sato Y, CowanCA, Chien KR, Melton DA. 2008. Marked differences in differentiation propensity among human embryonic stem cell lines. Nat Biotechnol 26: 313-315.
55. Ottolenghi S, Lanyon WG, Paul J, Williamson R, Weatherall DJ, Clegg JB, Pritchard J, Pootrakul S, Boon WH. 1974. The severe form of α thalassaemia is caused by a haemoglobin gene deletion. Nature 251: 389-392.
56. Papapetrou EP, Lee G, Malani N, Setty M, Riviere I, Tirunagari LM, Kadota K, Roth SL, Giardina P, Viale A, et al. 2010. Genomic safe harbors permit high β-globin transgene expression in thalassemia induced pluripotent stem cells. Nat Biotechnol 29: 73-78.
57. Park IH, Arora N, Huo H, Maherali N, Ahfeldt T, Shimamura A, Lensch MW, Cowan C, Hochedlinger K, Daley GQ. 2008a. Disease-specific induced pluripotent stem cells. Cell 134: 877-886.
58. Park IH, Lerou PH, Zhao R, Huo H, Daley GQ. 2008b. Generation of human-induced pluripotent stem cells. Nat Protoc 3: 1180-1186.
59. Paszty C, Brion CM, Manci E, Witkowska HE, Stevens ME, Mohandas N, RubinEM. 1997. Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease. Science 278: 876-878.
60. Pawliuk R, Westerman KA, Fabry ME, Payen E, Tighe R, Bouhassira EE, AcharyaSA, Ellis J, London IM, Eaves CJ, et al. 2001. Correction of sickle cell disease in transgenic mouse models by gene therapy. Science 294: 2368-2371.
61. Pickering SJ, Minger SL, Patel M, Taylor H, Black C, Burns CJ, Ekonomou A, Braude PR. 2005. Generation of a human embryonic stem cell line encoding the cystic fibrosis mutation ΔF508, using preimplantation genetic diagnosis. Reprod Biomed Online 10: 390-397.
62. Platt OS, Orkin SH, Dover G, Beardsley GP, Miller B, Nathan DG. 1984. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest 74: 652-656.
63. Qiu C, Olivier EN, Velho M, Bouhassira EE. 2008. Globin switches in yolk sac-like primitive and fetal-like definitive red blood cells produced from human embryonic stem cells. Blood 111: 2400-2408.
64. Reisner EG, Kostyu DD, Phillips G, Walker C, Dawson DV. 1987. Alloantibody responses in multiply transfused sickle cell patients. Tissue Antigens 30: 161-166.
65. Rideout WM III., Hochedlinger K, Kyba M, Daley GQ, Jaenisch R. 2002. Correction of a genetic defect by nuclear transplantation and combined cell and gene therapy. Cell 109: 17-27.
66. Rosse WF, Gallagher D, Kinney TR, Castro O, Dosik H, Moohr J, Wang W, LevyPS. 1990. Transfusion and alloimmunization in sickle cell disease. The Cooperative Study of Sickle Cell Disease. Blood 76: 1431-1437.
67. Sebastiano V, Maeder ML, Angstman JF, Haddad B, Khayter C, Yeo DT, GoodwinMJ, Hawkins JS, Ramirez CL, Batista LF, et al. 2011. In situ genetic correction of the sickle cell anemia mutation in human induced pluripotent stem cells using engineered zinc finger nucleases. Stem Cells 29: 1717-1726.
68. Skow LC, Burkhart BA, Johnson FM, Popp RA, Popp DM, Goldberg SZ, AndersonWF, Barnett LB, Lewis SE. 1983. A mouse model for β-thalassemia. Cell 34: 1043-1052.
69. Soldner F, Hockemeyer D, Beard C, Gao Q, Bell GW, Cook EG, Hargus G, Blak A, Cooper O, Mitalipova M, et al. 2009. Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 136: 964-977.
70. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, YamanakaS. 2007. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131: 861-872.
71. Taylor JM, Dozy A, Kan YW, Varmus HE, Lie-Injo LE, Ganesan J, Todd D. 1974. Genetic lesion in homozygous α thalassaemia (hydrops fetalis). Nature 251: 392-393.
72. Taylor CJ, Bolton EM, Pocock S, Sharples LD, Pedersen RA, Bradley JA. 2005. Banking on human embryonic stem cells: Estimating the number of donor cell lines needed for HLA matching. Lancet 366: 2019-2025.
73. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, MarshallVS, Jones JM. 1998. Embryonic stem cell lines derived from human blastocysts. Science 282: 1145-1147.
74. Tian X, Woll PS, Morris JK, Linehan JL, Kaufman DS. 2006. Hematopoietic engraftment of human embryonic stem cell-derived cells is regulated by recipient innate immunity. Stem Cells 24: 1370-1380.
75. Verlinsky Y, Strelchenko N, Kukharenko V, Rechitsky S, Verlinsky O, Galat V, Kuliev A. 2005. Human embryonic stem cell lines with genetic disorders. Reprod Biomed Online 10: 105-110.
76. Vichinsky EP, Earles A, Johnson RA, Hoag MS, Williams A, Lubin B. 1990. Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood. N Engl J Med 322: 1617-1621.
77. Wang L, Menendez P, Shojaei F, Li L, Mazurier F, Dick JE, Cerdan C, Levac K, Bhatia M. 2005. Generation of hematopoietic repopulating cells from human embryonic stem cells independent of ectopic HOXB4 expression. J Exp Med 201: 1603-1614.
78. Warren L, Manos PD, Ahfeldt T, Loh YH, Li H, Lau F, Ebina W, Mandal PK, SmithZD, Meissner A, et al. 2010. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 7: 618-630.
79. Weatherall DJ. 2001. Phenotype-genotype relationships in monogenic disease: Lessons from the thalassaemias. Nat Rev Genet 2: 245-255.
80. Wu LC, Sun CW, Ryan TM, Pawlik KM, Ren J, Townes TM. 2006. Correction of sickle cell disease by homologous recombination in embryonic stem cells. Blood 108: 1183-1188.
81. Xu J, Peng C, Sankaran VG, Shao Z, Esrick EB, Chong BG, Ippolito GC, FujiwaraY, Ebert BL, Tucker PW, et al. 2011. Correction of sickle cell disease in adult mice by interference with fetal hemoglobin silencing. Science 334: 993-996.
82. 0-thalassemia. Proc Natl Acad Sci 92: 11608-11612.
83. Yavarian M, Karimi M, Bakker E, Harteveld CL, Giordano PC. 2004. Response to hydroxyurea treatment in Iranian transfusion-dependent β-thalassemia patients. Haematologica 89: 1172-1178.
84. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, NieJ, Jonsdottir GA, Ruotti V, Stewart R, et al. 2007. Induced pluripotent stem cell lines derived from human somatic cells. Science 318: 1917-1920.
85. Yu J, Hu K, Smuga-Otto K, Tian S, Stewart R, Slukvin II., Thomson JA. 2009. Human induced pluripotent stem cells free of vector and transgene sequences. Science 324: 797-801.
86. Yusa K, Rashid ST, Strick-Marchand H, Varela I, Liu PQ, Paschon DE, MirandaE, Ordonez A, Hannan NR, Rouhani FJ, et al. 2011. Targeted gene correction of α1-antitrypsin deficiency in induced pluripotent stem cells. Nature 478: 391-394.
87. Zou J, Maeder ML, Mali P, Pruett-Miller SM, Thibodeau-Beganny S, Chou BK, Chen G, Ye Z, Park IH, Daley GQ, et al. 2009. Gene targeting of a disease-related gene in human induced pluripotent stem and embryonic stem cells. Cell Stem Cell 5: 97-110.